These Analysts Slash Their Forecasts On Lululemon Athletica Following Q4 Results - Lululemon Athletica ( NASDAQ:LULU )
Lululemon Athletica Inc LULU reported better-than-expected financial results for the fourth quarter on Thursday. Lululemon reported fourth-quarter revenue of $3.61 billion, beating the consensus estimate of $3.57 billion.
Palatin Technologies Touts Positive Results From Mid-Stage Study For Experimental Drug For Ulcerative Colitis, Halts Patients Enrollment Citing Strategic Focus - Palatin Techs ( AMEX:PTN )
Palatin's PL8177 achieved clinical remission in 33% of ulcerative colitis patients vs. 0% on placebo, with a 78% clinical response rate. The study stopped at 12 patients for strategic reasons, limiting statistical significance but supporting out-licensing discussions. Feel unsure about the ...
These Analysts Increase Their Forecasts On Braze Following Upbeat Results - Braze ( NASDAQ:BRZE )
Braze, Inc. BRZE posted better-than-expected fourth-quarter results after Thursday's closing bell. Braze reported quarterly earnings of 12 cents per share, which beat the analyst consensus estimate of five cents. Quarterly revenue came in at $160.4 million, beating the $155.72 million consensus ...
Bangkok declares 'disaster zone', buildings evacuated after Myanmar earthquake
The Stock Exchange of Thailand suspended trading across all exchanges on Friday while Honda and Nissan temporarily halted plant operations.
Prediction: This Artificial Intelligence ( AI ) Stock Will Join Nvidia, Meta Platforms, Apple, Microsoft, Amazon, and Alphabet in the Trillion-Dollar Club By The End of The Decade
The trillion-dollar club could be joined by an emerging cloud infrastructure player in the coming years.
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
- Received U.S. Food and Drug Administration ( FDA ) approval of Symvess™ ( acellular tissue engineered vessel-tyod ) for the treatment of extremity vascular trauma ...
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress
- Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD- ( L ) 1 resistant "hot" tumor patient population ...
What's Going On With Nike Stock?
Nike ( NYSE: NKE ) stock is underperforming in 2025 as I expected it would.*Stock prices used were the afternoon prices of March 25, 2025. The video was published on March 27, 2025.Continue reading ...
